Tregs and rethinking cancer immunotherapy

Journal of Clinical Investigation

Volumn 117, Issue 5, 2007, Pages 1167-1174

  Curiel, Tyler J ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CANCER VACCINE; CD4 ANTIGEN; CHEMOKINE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CLINICAL TRIAL; COLON CANCER; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUNG METASTASIS; MELANOMA; MONOCLONAL IMMUNOGLOBULINEMIA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SKIN LYMPHOMA; T CELL DEPLETION; T CELL LEUKEMIA; TREATMENT FAILURE; TUMOR REJECTION;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 34248194231     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31202     Document Type: Review

References (122)

1. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
2. Dunn, G.P., Old, L.J., and Schreiber, R.D. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360.
3. Zitvogel, L., Tesniere, A., and Kroemer, G. 2006. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6:715-727.
4. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer. 5:263-274.
5. Silverstein, A.M. 1989. A history of immunology. Academic Press. San Diego, California, USA. 422 pp.
6. Coley, W.B. 1893. The treatment of malignant tumors by repeated inoculums of erysipelas. Am. J. Med. Sci. 105:487-511.
7. McMichael, A.J., Gotch, F.M., Noble, G.R., and Beare, P.A. 1983. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309:13-17.
8. Nonacs, R., Humborg, C., Tam, J.P., and Steinman, R.M. 1992. Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T lymphocytes. J. Exp. Med. 176:519-529.
9. Crosnier, J., et al. 1981. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, haemodialysis patients. Lancet. 1:797-800.
10. Prehn, R., and Main, J.M. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:769-778.
11. Schreiber, H., Ward, P.L., Rowley, D.A., and Stauss, H.J. 1988. Unique tumor-specific antigens. Annu. Rev. Immunol. 6:465-483.
12. Stauss, H.J., Van Waes, C., Fink, M.A., Starr, B., and Schreiber, H. 1986. Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer. J. Exp. Med. 164:1516-1530.
13. Banchereau, J., and Steinman, R.M. 1998. Dendritic cells and the control of immunity. Nature. 392:245-252.
14. Hsu, F.J., et al. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
15. Nestle, F.O., et al. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
16. Nestle, F.O., Banchereau, J., and Hart, D. 2001. Dendritic cells: on the move from bench to bedside. Nat. Med. 7:761-765.
17. Rosenberg, S.A., Spiess, P., and Lafreniere, R. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 233:1318-1321.
18. Rosenberg, S.A., et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319:1676-1680.
19. Rosenberg, S.A., et al. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316:889-897.
20. Morgan, R.A., et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 314:126-129.
21. Pardoll, D.M. 1998. Cancer vaccines. Nat. Med. 4:525-531.
22. Gajewski, T.F., Meng, Y., and Harlin, H. 2006. Immune suppression in the tumor microenvironment. J. Immunother. 29:233-240.
23. Curiel, T.J., and Curiel, D.T. 2002. Tumor immunotherapy: inching toward the finish line. J. Clin. Invest. 109:311-312. doi:10.1172/JCI200215042.
24. Spiotto, M.T., Fu, Y.X., and Schreiber, H. 2003. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr. Opin. Immunol. 15:725-730.
25. Smyth, M.J., Dunn, G.P., and Schreiber, R.D. 2006. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90:1-50.
26. Pardoll, D. 2001. T cells and tumours. Nature. 411:1010-1012.
27. Pardoll, D. 2003. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21:807-839.
28. Wick, M., et al. 1997. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186:229-238.
29. Elgert, K.D., Alleva, D.G., and Mullins, D.W. 1998. Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 64:275-290.
30. Salazar-Onfray, F. 1999. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med. Oncol. 16:86-94.
31. Moore, K.W., de Waal Malefyt, R., Coffman, R.L., and O'Garra, A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765.
32. Li, M.O., Wan, Y.Y., Sanjabi, S., Robertson, A.K., and Flavell, R.A. 2006. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24:99-146.
33. Saunier, E.F., and Akhurst, R.J. 2006. TGF beta inhibition for cancer therapy. Curr. Cancer Drug Targets. 6:565-578.
34. Liu, V.C., et al. 2007. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumorderived TGF-beta. J. Immunol. 178:2883-2892.
35. Gabrilovich, D.I., et al. 1996. Production of vas cular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1096-1103.
36. Palmer, E. 2006. The T-cell antigen receptor: a logical response to an unknown ligand. J. Recept. Signal Transduct. Res. 26:367-378.
37. Roth, D.B. 2003. Restraining the V(D)J recombinase. Nat. Rev. Immunol. 3:656-666.
38. Krangel, M.S. 2003. Gene segment selection in V(D)J recombination: accessibility and beyond. Nat. Immunol. 4:624-630.
39. Sprent, J., and Surh, C.D. 2003. Knowing one's self: central tolerance revisited. Nat. Immunol. 4:303-304.
40. Rudensky, A.Y., Gavin, M., and Zheng, Y. 2006. FOXP3 and NFAT: partners in tolerance. Cell. 126:253-256.
41. Sakaguchi, S., Sakaguchi, N., Asano, M., and Toda, M. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alphachains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:115-1164.
42. Bach, J.F. 2003. Regulatory T cells under scrutiny. Nat. Rev. Immunol. 3:189-198.
43. Shevach, E.M. 2002. CD4+CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:389-400.
44. Marson, A., et al. 2007. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature. 445:931-935.
45. Zheng, Y., et al. 2007. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 445:936-940.
46. Gavin, M.A., et al. 2007. Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 445:771-775.
47. Wan, Y.Y., and Flavell, R.A. 2007. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature. 445:766-770.
48. Bursuker, I., and North, R.J. 1984. Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J. Exp. Med. 159:1312-1321.
49. Shimizu, J., Yamazaki, S., and Sakaguchi, S. 1999. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211-5218.
50. Tanaka, H., Tanaka, J., Kjaergaard, J., and Shu, S. 2002. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25:207-217.
51. Steitz, J., Bruck, J., Lenz, J., Knop, J., and Tuting, T. 2001. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alphainduced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61:8643-8646.
52. Sutmuller, R.P., et al. 2001. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823-832.
53. Grauer, O.M., et al. 2007. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int. J. Cancer. doi:10.1002/ijc.22607.
54. Chen, M.L., et al. 2005. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:419-424.
55. Nishikawa, H., Jager, E., Ritter, G., Old, L.J., and Gnjatic, S. 2005. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood. 106:1008-1011.
56. Levings, M.K., Sangregorio, R., and Roncarolo, M.G. 2001. Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193:1295-1302.
57. Wang, R.F. 2006. Immune suppression by tumorspecific CD4(+) regulatory T-cells in cancer. Semin. Cancer Biol. 16:73-79.
58. Wang, R.F., Peng, G., and Wang, H.Y. 2006. Regulatory T cells and Toll-like receptors in tumor immunity. Semin. Immunol. 18:136-142.
59. Woo, E.Y., et al. 2001. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61:4766-4772.
60. Curiel, T.J., et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-949.
61. Woo, E.Y., et al. 2002. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168:4272-4276.
62. Javia, L.R., and Rosenberg, S.A. 2003. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J. Immunother. 26:85-93.
63. Somasundaram, R., et al. 2002. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 62:5267-5272.
64. Wolf, A.M., et al. 2003. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9:606-612.
65. Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., and Takabayashi, A. 2003. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 98:1089-1099.
66. Liyanage, U.K., et al. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169:2756-2761.
67. Matsuura, K., et al. 2006. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer. 106:1227-1236.
68. Yang, Z.Z., Novak, A.J., Stenson, M.J., Witzig, T.E., and Ansell, S.M. 2006. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 107:3639-3646.
69. Chen, A., Liu, S., Park, D., Kang, Y., and Zheng, G. 2007. Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer Res. 67:1291-1298.
70. Carreras, J., et al. 2006. High numbers of tumorinfiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 108:2957-2964.
71. Alvaro, T., et al. 2005. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 11:1467-1473.
72. Tiemessen, M.M., et al. 2006. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J. Invest. Dermatol. 126:2217-2223.
73. Bluestone, J.A., and Abbas, A.K. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3:253-257.
74. Larmonier, N., et al. 2007. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol. Immunother. 56:48-59.
75. Curiel, T.J., et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562-567.
76. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6:295-307.
77. Wang, H.Y., et al. 2004. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 20:107-118.
78. Ghiringhelli, F., Menard, C., Martin, F., and Zitvogel, L. 2006. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 214:229-238.
79. Lim, H.W., Hillsamer, P., Banham, A.H., and Kim, C.H. 2005. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J. Immunol. 175:4180-4183.
80. Hori, S., Nomura, T., and Sakaguchi, S. 2003. Control of regulatory T cell development by the transcription factor foxp3. Science. 299:1057-1061.
81. Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4:330-336.
82. Curiel, T.J. 2007. Regulatory T cell development: is Foxp3 the decider? Nat. Med. 13:250-253.
83. Graca, L. 2005. New tools to identify regulatory T cells. Eur. J. Immunol. 35:1678-1680.
84. Roncador, G., et al. 2005. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur. J. Immunol. 35:1681-1691.
85. Fontenot, J.D., et al. 2005. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 22:329-341.
86. Wan, Y.Y., and Flavell, R.A. 2005. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc. Natl. Acad. Sci. U. S. A. 102:5126-5131.
87. Knutson, K., Curiel, T., Salazar, L., and Disis, M. 2003. Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematol. Oncol. Clin. North Am. 17:1051-1073.
88. Zou, W., et al. 2001. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7:1339-1346.
89. Wolf, D., et al. 2005. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11:8326-8331.
90. Bates, G.J., et al. 2006. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24:5373-5380.
91. Kobayashi, N., et al. 2007. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 13:902-911.
92. Prabhala, R.H., et al. 2006. Dysfunctional T regulatory cells in multiple myeloma. Blood. 107:301-304.
93. Foss, F.M. 2000. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin. Lymphoma. 1:110-116; discussion 117.
94. Barnett, B., Kryczek, I., Cheng, P., Zou, W., and Curiel, T.J. 2005. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. 54:369-377.
95. Knutson, K.L., et al. 2006. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177:84-91.
96. Dannull, J., et al. 2005. Enhancement of vaccinemediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115:3623-3633. doi:10.1172/JCI25947.
97. Chesney, J., Rasku, M., Clem, A., and Miller, D. 2006. Denileukin diftitox depletes T regulatory cells and causes regression of melanoma metastases in humans [abstract]. European Journal of Cancer Supplements. 4:84.
98. Mahnke, K., et al. 2007. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer. doi:10.1002/ijc.22617.
99. Attia, P., Maker, A.V., Haworth, L.R., Rogers-Freezer, L., and Rosenberg, S.A. 2005. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28:582-592.
100. Jarnicki, A.G., Lysaght, J., Todryk, S., and Mills, K.H. 2006. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. 177:896-904.
101. Rüter, J., et al. 2007. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost efficacy. Front. Biosci. In press.
102. Li, B., et al. 2006. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSFsecreting cancer immunotherapy. Clin. Cancer Res. 12:6808-6816.
103. Zhou, G., Drake, C.G., and Levitsky, H.I. 2006. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 107:628-636.
104. Banerjee, D.K., et al. 2006. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 108:2655-2661.
105. Ahmadzadeh, M., and Rosenberg, S.A. 2006. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood. 107:2409-2414.
106. Berek, J.S., Schultes, B.C., and Nicodemus, C.F. 2003. Biologic and immunologic therapies for ovarian cancer. J. Clin. Oncol. 21:168-174.
107. Windbichler, G.H., et al. 2000. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer. 82:1138-1144.
108. Rongcun, Y., et al. 1998. Interferon gamma impairs the ability of monocyte-derived dendritic cells to present tumour-specific and allo-specific antigens and reduces their expression of CD1A, CD80 and CD4. Cytokine. 10:747-755.
109. Kudo-Saito, C., Schlom, J., Camphausen, K., Coleman, C.N., and Hodge, J.W. 2005. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin. Cancer Res. 11:4533-4544.
110. Taieb, J., et al. 2006. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176:2722-2729.
111. Nair, S., Boczkowski, D., Fassnacht, M., Pisetsky, D., and Gilboa, E. 2007. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 67:371-380.
112. Wei, S., et al. 2005. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 65:5020-5026.
113. Taniguchi, M., Harada, M., Kojo, S., Nakayama, T., and Wakao, H. 2003. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21:483-513.
114. Almand, B., et al. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166:678-689.
115. Kusmartsev, S., and Gabrilovich, D.I. 2006. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 55:237-245.
116. Kryczek, I., et al. 2006. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203:871-881.
117. Terabe, M., et al. 2005. A nonclassical non-Valpha-14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202:1627-1633.
118. Mahic, M., Yaqub, S., Johansson, C.C., Tasken, K., and Aandahl, E.M. 2006. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J. Immunol. 177:246-254.
119. Polanczyk, M.J., et al. 2004. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J. Immunol. 173:2227-2230.
120. Tisdale, J.F., Dunn, D.E., and Maciejewski, J. 2000. Cyclophosphamide and other new agents for the treatment of severe aplastic anemia. Semin. Hematol. 37:102-109.
121. Berd, D., and Mastrangelo, M.J. 1987. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res. 47:3317-3321.
122. Ghiringhelli, F., et al. 2007. Metronomic cyclophosphamide regimen selectively depletes CD4(+)CD25 (+) regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56:641-648.